Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation.
PLoS One
; 7(10): e46908, 2012.
Article
en En
| MEDLINE
| ID: mdl-23056525
ABSTRACT
BACKGROUND:
Among the more common human malignancies, invasive ductal carcinoma of the pancreas has the worst prognosis. The poor outcome seems to be attributable to difficulty in early detection.METHODS:
We compared the plasma protein profiles of 112 pancreatic cancer patients with those of 103 sex- and age-matched healthy controls (Cohort 1) using a newly developed matrix-assisted laser desorption/ionization (oMALDI) QqTOF (quadrupole time-of-flight) mass spectrometry (MS) system.RESULTS:
We found that hemi-truncated apolipoprotein AII dimer (ApoAII-2; 17252 m/z), unglycosylated apolipoprotein CIII (ApoCIII-0; 8766 m/z), and their summed value were significantly decreased in the pancreatic cancer patients [Pâ=â1.36×10(-21), Pâ=â4.35×10(-14), and Pâ=â1.83×10(-24) (Mann-Whitney U-test); area-under-curve values of 0.877, 0.798, and 0.903, respectively]. The significance was further validated in a total of 1099 plasma/serum samples, consisting of 2 retrospective cohorts [Cohort 2 (nâ=â103) and Cohort 3 (nâ=â163)] and a prospective cohort [Cohort 4 (nâ=â833)] collected from 8 medical institutions in Japan and Germany.CONCLUSIONS:
We have constructed a robust quantitative MS profiling system and used it to validate alterations of modified apolipoproteins in multiple cohorts of patients with pancreatic cancer.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Apolipoproteínas
Tipo de estudio:
Prognostic_studies
/
Screening_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
PLoS One
Asunto de la revista:
CIENCIA
/
MEDICINA
Año:
2012
Tipo del documento:
Article
País de afiliación:
Japón